ISHRAK OMAR

SEC source: 0000318154-26-000133 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,485.9046

F1 · balance_after: These shares include 460 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000104 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,358.7361

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 418 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000071 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,693.7361

F1 · balance_after: These shares include 418 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000079 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,507.5436

F1 · balance_after: These shares include 338 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000061 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,241.9302

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 291 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-015857 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,084.4994

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 255 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-013770 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,275.4994

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 255 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-010793 · form4.xml · derivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,838.215

Underlying: Common Stock · 1,376.046 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit represents the right to receive the cash value of one share of Intel common stock.

F2 · derivative.exercise_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

F2 · derivative.expiration_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

SEC source: 0001127602-24-030212 · form4.xml · derivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,462.169

Underlying: Common Stock · 1,539.409 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit represents the right to receive the cash value of one share of Intel common stock.

F2 · derivative.exercise_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

F2 · derivative.expiration_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

SEC source: 0001127602-24-026625 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,081.0807

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule

F2 · balance_after: These shares include 190 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-024724 · form4.xml · derivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,922.76

Underlying: Common Stock · 1,306.985 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit represents the right to receive the cash value of one share of Intel common stock.

F2 · derivative.exercise_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

F2 · derivative.expiration_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

F3 · balance_after: Includes 9.986 units acquired via dividend reinvestment in September 2024.

SEC source: 0001127602-24-022108 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,833.1978

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule

F2 · balance_after: These shares include 163 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-019900 · form4.xml · derivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,605.789

Underlying: Common Stock · 1,009.041 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit represents the right to receive the cash value of one share of Intel common stock.

F2 · derivative.exercise_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

F2 · derivative.expiration_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

F3 · balance_after: Includes 2.453 units acquired via dividend reinvestment in June 2024.

SEC source: 0001127602-24-017811 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,695.6673

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 134 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-014992 · form4.xml · derivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,403

Underlying: Common Stock · 7,403 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F2 · derivative.exercise_date: The reporting person elected to defer settlement of their grant of restricted stock units until the termination of their service to the Intel Corporation Board of Directors.

F3 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) or the date of the 2025 Annual Stockholders' Meeting.

F2 · derivative.expiration_date: The reporting person elected to defer settlement of their grant of restricted stock units until the termination of their service to the Intel Corporation Board of Directors.

F3 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) or the date of the 2025 Annual Stockholders' Meeting.

SEC source: 0001127602-24-014686 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,976.6673

F1 · balance_after: The Restricted Stock Units (RSUs) were granted, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 134 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-011841 · form4.xml · derivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 594.295

Underlying: Common Stock · 594.295 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit represents the right to receive the cash value of one share of Intel common stock.

F2 · derivative.exercise_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

F2 · derivative.expiration_date: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.

SEC source: 0001127602-23-026974 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,813.1172

F1 · balance_after: The Restricted Stock Units (RSUs) were granted, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 87 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0000950170-23-055251 · ownership.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,235

F1 · shares: The shares reported in this transaction represent an initial, one-time grant of Restricted Stock Units ("RSUs") issued pursuant to the Issuer's non-employee director compensation policy and the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in equal annual installments over three years from October 23, 2023, subject to the Reporting Person's continued service as a director of the Issuer on each such vesting date.

SEC source: 0001127602-23-022310 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,525.2516

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 40 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001209191-23-044553 · doc4a.xml · derivative · entry 4

Compute Health Sponsor LLC · CIK 0001828596 · Director · 10% owner

ISHRAK OMAR · CIK 0001523102 · Director · 10% owner

Nehme Jean · CIK 0001843660 · Director · 10% owner

Fink Joshua A · CIK 0001414107 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 21,442,500 shares

Expires not disclosed

F6 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date.

F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").

F2 · kind: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.

F2 · price: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.

F6 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date.

F6 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date.

F3 · ownership.direct: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein.

SEC source: 0001209191-23-044553 · doc4a.xml · nonDerivative · entry 3

Compute Health Sponsor LLC · CIK 0001828596 · Director · 10% owner

ISHRAK OMAR · CIK 0001523102 · Director · 10% owner

Nehme Jean · CIK 0001843660 · Director · 10% owner

Fink Joshua A · CIK 0001414107 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").

F5 · kind: Pursuant to the terms of the Business Combination Agreement, each of the 1,926,948 shares of Class A Common Stock held by the Sponsor were canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value.

F5 · price: Pursuant to the terms of the Business Combination Agreement, each of the 1,926,948 shares of Class A Common Stock held by the Sponsor were canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value.

F3 · ownership.direct: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein.

SEC source: 0001209191-23-044553 · doc4a.xml · nonDerivative · entry 2

Compute Health Sponsor LLC · CIK 0001828596 · Director · 10% owner

ISHRAK OMAR · CIK 0001523102 · Director · 10% owner

Nehme Jean · CIK 0001843660 · Director · 10% owner

Fink Joshua A · CIK 0001414107 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,926,948

F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").

F4 · kind: Pursuant to the terms of that certain Contribution Agreement, dated as of May 2, 2023, by and between the issuer and the Sponsor, 161,379 shares of Class A Common Stock held by the Sponsor were contributed to the capital of the issuer.

F4 · price: Pursuant to the terms of that certain Contribution Agreement, dated as of May 2, 2023, by and between the issuer and the Sponsor, 161,379 shares of Class A Common Stock held by the Sponsor were contributed to the capital of the issuer.

F3 · ownership.direct: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein.

SEC source: 0001209191-23-044553 · doc4a.xml · nonDerivative · entry 1

Compute Health Sponsor LLC · CIK 0001828596 · Director · 10% owner

ISHRAK OMAR · CIK 0001523102 · Director · 10% owner

Nehme Jean · CIK 0001843660 · Director · 10% owner

Fink Joshua A · CIK 0001414107 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,088,327

F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").

F2 · kind: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.

F2 · price: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.

F3 · ownership.direct: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein.

SEC source: 0001209191-23-044453 · doc4.xml · derivative · entry 4

Compute Health Sponsor II LLC · CIK 0001857472 · Director · 10% owner

ISHRAK OMAR · CIK 0001523102 · Director · 10% owner

Nehme Jean · CIK 0001843660 · Director · 10% owner

Fink Joshua A · CIK 0001414107 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 21,442,500 shares

Expires not disclosed

F6 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date.

F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").

F2 · kind: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.

F2 · price: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.

F6 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date.

F6 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date.

F3 · ownership.direct: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein.

SEC source: 0001209191-23-044453 · doc4.xml · nonDerivative · entry 3

Compute Health Sponsor II LLC · CIK 0001857472 · Director · 10% owner

ISHRAK OMAR · CIK 0001523102 · Director · 10% owner

Nehme Jean · CIK 0001843660 · Director · 10% owner

Fink Joshua A · CIK 0001414107 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").

F5 · kind: Pursuant to the terms of the Business Combination Agreement, each of the 1,926,948 shares of Class A Common Stock held by the Sponsor were canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value.

F5 · price: Pursuant to the terms of the Business Combination Agreement, each of the 1,926,948 shares of Class A Common Stock held by the Sponsor were canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value.

F3 · ownership.direct: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein.

SEC source: 0001209191-23-044453 · doc4.xml · nonDerivative · entry 2

Compute Health Sponsor II LLC · CIK 0001857472 · Director · 10% owner

ISHRAK OMAR · CIK 0001523102 · Director · 10% owner

Nehme Jean · CIK 0001843660 · Director · 10% owner

Fink Joshua A · CIK 0001414107 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,926,948

F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").

F4 · kind: Pursuant to the terms of that certain Contribution Agreement, dated as of May 2, 2023, by and between the issuer and the Sponsor, 161,379 shares of Class A Common Stock held by the Sponsor were contributed to the capital of the issuer.

F4 · price: Pursuant to the terms of that certain Contribution Agreement, dated as of May 2, 2023, by and between the issuer and the Sponsor, 161,379 shares of Class A Common Stock held by the Sponsor were contributed to the capital of the issuer.

F3 · ownership.direct: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein.

SEC source: 0001209191-23-044453 · doc4.xml · nonDerivative · entry 1

Compute Health Sponsor II LLC · CIK 0001857472 · Director · 10% owner

ISHRAK OMAR · CIK 0001523102 · Director · 10% owner

Nehme Jean · CIK 0001843660 · Director · 10% owner

Fink Joshua A · CIK 0001414107 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,088,327

F1 · kind: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").

F2 · kind: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.

F2 · price: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.

F3 · ownership.direct: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein.

SEC source: 0001127602-23-016637 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,400.635

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 40 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015607 · form4.xml · derivative · entry 3

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,828 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F4 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of May 12, 2023 or the date of the 2023 Annual Stockholders' Meeting.

F4 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of May 12, 2023 or the date of the 2023 Annual Stockholders' Meeting.

SEC source: 0001127602-23-015607 · form4.xml · derivative · entry 2

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,152

Underlying: Common Stock · 7,152 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F2 · derivative.exercise_date: The reporting person elected to defer settlement of their grant of restricted stock units until the termination of their service to the Intel Corporation Board of Directors.

F3 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) and the date of the 2024 Annual Stockholders' Meeting.

F2 · derivative.expiration_date: The reporting person elected to defer settlement of their grant of restricted stock units until the termination of their service to the Intel Corporation Board of Directors.

F3 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) and the date of the 2024 Annual Stockholders' Meeting.

SEC source: 0001127602-23-015607 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

SEC source: 0001127602-23-014374 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,461.635

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 40 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-022303 · form4.xml · nonDerivative · entry 2

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 86

SEC source: 0001127602-22-025333 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,301.9056

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 18 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-020847 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,069.5998

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include eight Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-015177 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,930.7414

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

SEC source: 0001127602-22-014676 · form4.xml · derivative · entry 3

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,720 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F3 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) or the date of the 2022 Annual Stockholders' Meeting.

F3 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) or the date of the 2022 Annual Stockholders' Meeting.

SEC source: 0001127602-22-014676 · form4.xml · derivative · entry 2

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,828

Underlying: Common Stock · 4,828 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of May 12, 2023 or the date of the 2023 Annual Stockholders' Meeting.

F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of May 12, 2023 or the date of the 2023 Annual Stockholders' Meeting.

SEC source: 0001127602-22-014676 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,944

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel common stock.

SEC source: 0001127602-22-013338 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,075.7414

F1 · balance_after: The Restricted Stock Units (RSUs) were granted, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-22-006568 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,224

F1 · price: This transaction was executed in multiple trades at prices ranging from $45.075 to $45.125. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-21-027958 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,199

F1 · price: This transaction was executed in multiple trades at prices ranging from $48.01 to $48.04. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-21-023488 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 935

F1 · balance_after: The Restricted Stock Units were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-21-017048 · form4.xml · derivative · entry 3

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,720

Underlying: Common Stock · 3,720 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation (the "Company") common stock.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation (the "Company") common stock.

F3 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) or the date of the 2022 Annual Stockholders' Meeting.

F3 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) or the date of the 2022 Annual Stockholders' Meeting.

SEC source: 0001127602-21-017048 · form4.xml · derivative · entry 2

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,721 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation (the "Company") common stock.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation (the "Company") common stock.

F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) and the date of the 2021 Annual Stockholders' Meeting.

F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) and the date of the 2021 Annual Stockholders' Meeting.

SEC source: 0001127602-21-017048 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,199

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation (the "Company") common stock.

SEC source: 0001127602-21-003590 · form4.xml · derivative · entry 2

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 810 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock.

F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of the grant date, unless that date falls on a non-business date, in which case the next business date shall apply.

F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of the grant date, unless that date falls on a non-business date, in which case the next business date shall apply.

SEC source: 0001127602-21-003590 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,478

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock.

SEC source: 0001127602-20-031212 · form4.xml · nonDerivative · entry 2

ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · Joint Revocable Trust

Disclosed balance after: 8,650

F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's children. The reporting person's spouse and the reporting person are co-trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.